

Wolfgang Wick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5349445/publications.pdf>

Version: 2024-02-01

615
papers

65,679
citations

872

117
h-index

1051

234
g-index

687
all docs

687
docs citations

687
times ranked

48932
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 1963-1972. | 1.6 | 3,222 |
| 2 | Bevacizumab plus Radiotherapyâ€“Temozolomide for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 709-722. | 27.0 | 2,078 |
| 3 | DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474. | 27.8 | 1,872 |
| 4 | Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437. | 16.8 | 1,551 |
| 5 | An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. <i>Nature</i> , 2011, 478, 197-203. | 27.8 | 1,514 |
| 6 | Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. <i>Acta Neuropathologica</i> , 2009, 118, 469-474. | 7.7 | 1,020 |
| 7 | Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 707-715. | 10.7 | 980 |
| 8 | EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186. | 27.6 | 826 |
| 9 | European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329. | 10.7 | 816 |
| 10 | Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 376, 1027-1037. | 27.0 | 810 |
| 11 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108. | 10.7 | 800 |
| 12 | Brain tumour cells interconnect to a functional and resistant network. <i>Nature</i> , 2015, 528, 93-98. | 27.8 | 787 |
| 13 | Rindopimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385. | 10.7 | 776 |
| 14 | NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. <i>Journal of Clinical Oncology</i> , 2009, 27, 5874-5880. | 1.6 | 743 |
| 15 | Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. <i>Nature Medicine</i> , 2002, 8, 808-815. | 30.7 | 741 |
| 16 | Correlation of O ⁶ -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. <i>Journal of Clinical Oncology</i> , 2008, 26, 4189-4199. | 1.6 | 725 |
| 17 | Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. <i>Acta Neuropathologica</i> , 2010, 120, 707-718. | 7.7 | 719 |
| 18 | Glioma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15017. | 30.5 | 718 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 377, 1954-1963. | 27.0 | 670 |
| 20 | EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology</i> , The, 2014, 15, e395-e403. | 10.7 | 647 |
| 21 | MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. <i>Nature Reviews Neurology</i> , 2010, 6, 39-51. | 10.1 | 644 |
| 22 | Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245. | 27.8 | 637 |
| 23 | Stem Cell-Related Self-Renewal Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3015-3024. | 1.6 | 631 |
| 24 | Glutamatergic synaptic input to glioma cells drives brain tumour progression. <i>Nature</i> , 2019, 573, 532-538. | 27.8 | 628 |
| 25 | A vaccine targeting mutant IDH1 induces antitumour immunity. <i>Nature</i> , 2014, 512, 324-327. | 27.8 | 613 |
| 26 | Standards of care for treatment of recurrent glioblastoma—are we there yet?. <i>Neuro-Oncology</i> , 2013, 15, 4-27. | 1.2 | 592 |
| 27 | Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion. <i>Cancer Research</i> , 2012, 72, 5435-5440. | 0.9 | 591 |
| 28 | DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694. | 10.7 | 586 |
| 29 | Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542. | 10.7 | 582 |
| 30 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113. | 1.2 | 543 |
| 31 | Gadolinium Retention in the Dentate Nucleus and Globus Pallidus Is Dependent on the Class of Contrast Agent. <i>Radiology</i> , 2015, 275, 783-791. | 7.3 | 507 |
| 32 | Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1064-1075. | 1.2 | 485 |
| 33 | MGMT testing—the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , 2014, 10, 372-385. | 10.1 | 454 |
| 34 | Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1168-1174. | 1.6 | 450 |
| 35 | Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. <i>Oncogene</i> , 2007, 26, 186-197. | 5.9 | 440 |
| 36 | Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force. <i>European Journal of Neurology</i> , 2010, 17, 1124-1133. | 3.3 | 428 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2016, 17, 1521-1532. | 10.7 | 396 |
| 38 | Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA09): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 678-688. | 13.7 | 384 |
| 39 | SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo. <i>Cancer Research</i> , 2004, 64, 7954-7961. | 0.9 | 380 |
| 40 | ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an integrated diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015, 129, 133-146. | 7.7 | 378 |
| 41 | Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018, 24, 1192-1203. | 30.7 | 359 |
| 42 | Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98. | 1.2 | 346 |
| 43 | Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. <i>Radiology</i> , 2016, 280, 880-889. | 7.3 | 345 |
| 44 | EANO ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. <i>Annals of Oncology</i> , 2017, 28, iv84-iv99. | 1.2 | 331 |
| 45 | Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. <i>Clinical Cancer Research</i> , 2008, 14, 2900-2908. | 7.0 | 319 |
| 46 | Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. <i>Acta Neuropathologica</i> , 2018, 136, 181-210. | 7.7 | 308 |
| 47 | Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet</i> , The, 2017, 390, 1645-1653. | 13.7 | 307 |
| 48 | ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. <i>Acta Neuropathologica</i> , 2013, 126, 443-451. | 7.7 | 304 |
| 49 | Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166. | 7.7 | 298 |
| 50 | O ⁶ -methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. <i>Journal of Neurochemistry</i> , 2006, 96, 766-776. | 3.9 | 290 |
| 51 | How to use and assess qualitative research methods. <i>Neurological Research and Practice</i> , 2020, 2, 14. | 2.0 | 290 |
| 52 | Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors. <i>Frontiers in Immunology</i> , 2014, 5, 673. | 4.8 | 284 |
| 53 | Automated brain extraction of multisequence MRI using artificial neural networks. <i>Human Brain Mapping</i> , 2019, 40, 4952-4964. | 3.6 | 284 |
| 54 | cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. <i>Acta Neuropathologica</i> , 2018, 135, 639-642. | 7.7 | 281 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Neuroprotection by Hypoxic Preconditioning Requires Sequential Activation of Vascular Endothelial Growth Factor Receptor and Akt. <i>Journal of Neuroscience</i> , 2002, 22, 6401-6407. | 3.6 | 279 |
| 56 | RNA Interference Targeting Transforming Growth Factor- β 2 Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity <i>In vivo</i> . <i>Cancer Research</i> , 2004, 64, 7596-7603. | 0.9 | 275 |
| 57 | IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. <i>Acta Neuropathologica</i> , 2015, 129, 867-873. | 7.7 | 272 |
| 58 | Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2019, 20, 728-740. | 10.7 | 271 |
| 59 | Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon- β and Protein Kinase R. <i>Stem Cells</i> , 2009, 27, 909-919. | 3.2 | 268 |
| 60 | Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. <i>Acta Neuropathologica</i> , 2014, 128, 551-559. | 7.7 | 268 |
| 61 | <i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2057-2064. | 7.0 | 264 |
| 62 | IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. <i>Scientific Reports</i> , 2015, 5, 16238. | 3.3 | 259 |
| 63 | Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , 2013, 126, 907-915. | 7.7 | 254 |
| 64 | Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. <i>Acta Neuropathologica</i> , 2015, 129, 679-693. | 7.7 | 254 |
| 65 | Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. <i>Oncotarget</i> , 2014, 5, 1038-1051. | 1.8 | 248 |
| 66 | Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2735-2744. | 1.6 | 244 |
| 67 | Brain Tumor Segmentation and Radiomics Survival Prediction: Contribution to the BRATS 2017 Challenge. <i>Lecture Notes in Computer Science</i> , 2018, , 287-297. | 1.3 | 244 |
| 68 | Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3357-3361. | 1.6 | 237 |
| 69 | Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. <i>Acta Neuropathologica</i> , 2015, 130, 407-417. | 7.7 | 237 |
| 70 | Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498. | 12.8 | 237 |
| 71 | Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. <i>Radiology</i> , 2016, 281, 907-918. | 7.3 | 236 |
| 72 | No New-Net. <i>Lecture Notes in Computer Science</i> , 2019, , 234-244. | 1.3 | 233 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | A vaccine targeting mutant IDH1 in newly diagnosed glioma. <i>Nature</i> , 2021, 592, 463-468. | 27.8 | 232 |
| 74 | Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. <i>Journal of Neuro-Oncology</i> , 2001, 53, 177-185. | 2.9 | 231 |
| 75 | Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response. <i>Clinical Cancer Research</i> , 2016, 22, 5765-5771. | 7.0 | 230 |
| 76 | Malignant glioma biology: Role for TGF- β in growth, motility, angiogenesis, and immune escape. <i>Microscopy Research and Technique</i> , 2001, 52, 401-410. | 2.2 | 224 |
| 77 | Predictive impact of <i>MGMT</i> promoter methylation in glioblastoma of the elderly. <i>International Journal of Cancer</i> , 2012, 131, 1342-1350. | 5.1 | 220 |
| 78 | Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutation. <i>Neurology</i> , 2013, 81, 1515-1522. | 1.1 | 211 |
| 79 | Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910. | 7.7 | 203 |
| 80 | A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1146-1156. | 1.2 | 197 |
| 81 | Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 793-803. | 7.7 | 195 |
| 82 | Tumor microtubules convey resistance to surgical lesions and chemotherapy in gliomas. <i>Neuro-Oncology</i> , 2017, 19, 1316-1326. | 1.2 | 190 |
| 83 | Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , 2018, 136, 273-291. | 7.7 | 190 |
| 84 | EANO guideline on the diagnosis and treatment of vestibular schwannoma. <i>Neuro-Oncology</i> , 2020, 22, 31-45. | 1.2 | 190 |
| 85 | High-Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images. <i>Investigative Radiology</i> , 2015, 50, 805-810. | 6.2 | 188 |
| 86 | Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016, 18, 549-556. | 1.2 | 187 |
| 87 | Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014, 128, 561-571. | 7.7 | 176 |
| 88 | Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 848-857. | 1.2 | 170 |
| 89 | Molecular neuro-oncology in clinical practice: a new horizon. <i>Lancet Oncology</i> , The, 2013, 14, e370-e379. | 10.7 | 167 |
| 90 | Relaxation-compensated CEST-MRI of the human brain at 7 T: Unbiased insight into NOE and amide signal changes in human glioblastoma. <i>NeuroImage</i> , 2015, 112, 180-188. | 4.2 | 165 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222. | 7.7 | 163 |
| 92 | Therapeutic options in recurrent glioblastoma—An update. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 389-408. | 4.4 | 161 |
| 93 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 731-739. | 1.6 | 159 |
| 94 | Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. <i>Neuro-Oncology</i> , 2012, 14, iv100-iv108. | 1.2 | 154 |
| 95 | Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. <i>Journal of Clinical Oncology</i> , 2006, 24, 4412-4417. | 1.6 | 152 |
| 96 | mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 409-414. | 7.1 | 152 |
| 97 | Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration. <i>Investigative Radiology</i> , 2015, 50, 743-748. | 6.2 | 151 |
| 98 | Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. <i>Acta Neuropathologica</i> , 2017, 133, 629-644. | 7.7 | 146 |
| 99 | cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). <i>Acta Neuropathologica</i> , 2018, 135, 481-484. | 7.7 | 145 |
| 100 | New (alternative) temozolomide regimens for the treatment of glioma. <i>Neuro-Oncology</i> , 2009, 11, 69-79. | 1.2 | 142 |
| 101 | Association of General Anesthesia vs Procedural Sedation With Functional Outcome Among Patients With Acute Ischemic Stroke Undergoing Thrombectomy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1283. | 7.4 | 140 |
| 102 | Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 544-558. | 1.7 | 137 |
| 103 | Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma. <i>PLoS ONE</i> , 2013, 8, e57924. | 2.5 | 137 |
| 104 | Primary Central Nervous System Lymphoma and Atypical Glioblastoma: Multiparametric Differentiation by Using Diffusion-, Perfusion-, and Susceptibility-weighted MR Imaging. <i>Radiology</i> , 2014, 272, 843-850. | 7.3 | 137 |
| 105 | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC Tj ETQq1 1 0.784314 rgBT /Ov Oncology, The, 2021, 22, 813-823. | 10.7 | 132 |
| 106 | Epilepsy meets cancer: when, why, and what to do about it?. <i>Lancet Oncology, The</i> , 2012, 13, e375-e382. | 10.7 | 131 |
| 107 | Optimal management of elderly patients with glioblastoma. <i>Cancer Treatment Reviews</i> , 2013, 39, 350-357. | 7.7 | 131 |
| 108 | Transforming Growth Factors β 1 (TGF- β 1) and TGF- β 2 Promote Glioma Cell Migration via Up-Regulation of α 3 Integrin Expression. <i>Biochemical and Biophysical Research Communications</i> , 2000, 268, 607-611. | 2.1 | 130 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. <i>Neuro-Oncology</i> , 2016, 18, now133. | 1.2 | 130 |
| 110 | Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects. <i>Clinical Cancer Research</i> , 2014, 20, 5612-5619. | 7.0 | 129 |
| 111 | Tweety-Homolog 1 Drives Brain Colonization of Gliomas. <i>Journal of Neuroscience</i> , 2017, 37, 6837-6850. | 3.6 | 129 |
| 112 | Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide. <i>Journal of Clinical Oncology</i> , 2009, 27, 1257-1261. | 1.6 | 128 |
| 113 | Molecular diagnostics of gliomas: the clinical perspective. <i>Acta Neuropathologica</i> , 2010, 120, 585-592. | 7.7 | 127 |
| 114 | Costimulatory Protein 41gB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness. <i>Clinical Cancer Research</i> , 2012, 18, 105-117. | 7.0 | 126 |
| 115 | The Endogenous Tryptophan Metabolite and NAD ⁺ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress. <i>Cancer Research</i> , 2013, 73, 3225-3234. | 0.9 | 126 |
| 116 | The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e19823. | 2.5 | 126 |
| 117 | GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas. <i>Clinical Cancer Research</i> , 2010, 16, 3851-3859. | 7.0 | 125 |
| 118 | Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374. | 10.1 | 125 |
| 119 | Targeting Self-Renewal in High-Grade Brain Tumors Leads to Loss of Brain Tumor Stem Cells and Prolonged Survival. <i>Cell Stem Cell</i> , 2014, 15, 185-198. | 11.1 | 123 |
| 120 | Malignant Melanoma S3-Guideline –Diagnosis, Therapy and Follow-up of Melanoma– JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-116. | 0.8 | 122 |
| 121 | Pathway inhibition: emerging molecular targets for treating glioblastoma. <i>Neuro-Oncology</i> , 2011, 13, 566-579. | 1.2 | 121 |
| 122 | Transforming growth factor- β 2 and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. <i>Cell and Tissue Research</i> , 1999, 296, 221-227. | 2.9 | 120 |
| 123 | Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. <i>Journal of Neurochemistry</i> , 2012, 122, 444-455. | 3.9 | 120 |
| 124 | Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. <i>Acta Neuropathologica</i> , 2017, 133, 1-3. | 7.7 | 120 |
| 125 | Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma. <i>PLoS ONE</i> , 2012, 7, e33449. | 2.5 | 120 |
| 126 | Transforming Growth Factor- β 4: A Molecular Target for the Future Therapy of Glioblastoma. <i>Current Pharmaceutical Design</i> , 2006, 12, 341-349. | 1.9 | 119 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Assessing the predictability of <i>IDH</i> mutation and <i>MGMT</i> methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. <i>Neuro-Oncology</i> , 2018, 20, 1661-1671. | 1.2 | 119 |
| 128 | Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. <i>Cancer Research</i> , 2002, 62, 7139-42. | 0.9 | 118 |
| 129 | Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. <i>International Journal of Cancer</i> , 2014, 135, 1822-1831. | 5.1 | 117 |
| 130 | Treatment of glioblastoma in adults. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641879045. | 3.5 | 117 |
| 131 | Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF- β -dependent HIF-1 α -mediated induction of CXCL12. <i>Brain</i> , 2006, 129, 2426-2435. | 7.6 | 116 |
| 132 | CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413. | 7.7 | 116 |
| 133 | Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. <i>Neuro-Oncology</i> , 2014, 16, 696-706. | 1.2 | 115 |
| 134 | Tumor Infiltration in Enhancing and Non-Enhancing Parts of Glioblastoma: A Correlation with Histopathology. <i>PLoS ONE</i> , 2017, 12, e0169292. | 2.5 | 113 |
| 135 | Bevacizumab and Recurrent Malignant Gliomas: A European Perspective. <i>Journal of Clinical Oncology</i> , 2010, 28, e188-e189. | 1.6 | 112 |
| 136 | Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2166-2175. | 1.6 | 112 |
| 137 | Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. <i>Nature Communications</i> , 2020, 11, 931. | 12.8 | 112 |
| 138 | Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. <i>Journal of Neurochemistry</i> , 2005, 93, 992-999. | 3.9 | 111 |
| 139 | A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 6304-6313. | 7.0 | 111 |
| 140 | Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. <i>Nature Cancer</i> , 2021, 2, 723-740. | 13.2 | 110 |
| 141 | Molecular determinants of glioma cell migration and invasion. <i>Journal of Neurosurgery</i> , 2001, 94, 978-984. | 1.6 | 109 |
| 142 | Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases. <i>Clinical Cancer Research</i> , 2016, 22, 6078-6087. | 7.0 | 109 |
| 143 | Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. <i>Acta Neuropathologica</i> , 2018, 135, 955-963. | 7.7 | 109 |
| 144 | Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1262-1275. | 1.2 | 109 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Downfieldâ€œNOEâ€œsuppressed amideâ€œCESTâ€œMRI at 7 Tesla provides a unique contrast in human glioblastoma. <i>Magnetic Resonance in Medicine</i> , 2017, 77, 196-208. | 3.0 | 108 |
| 146 | Aryl hydrocarbon receptor inhibition downregulates the TGF- β 2/Smad pathway in human glioblastoma cells. <i>Oncogene</i> , 2009, 28, 2593-2605. | 5.9 | 106 |
| 147 | Diagnostic challenges in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1588-1598. | 1.2 | 106 |
| 148 | Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011, 13, 353-361. | 1.2 | 105 |
| 149 | Phase II Study of Radiotherapy and Temozolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016, 22, 4797-4806. | 7.0 | 105 |
| 150 | Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 702-710. | 4.1 | 103 |
| 151 | PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. <i>Oncogene</i> , 1999, 18, 3936-3943. | 5.9 | 102 |
| 152 | Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. <i>Neurology</i> , 2014, 82, 1684-1692. | 1.1 | 101 |
| 153 | N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non- <i>MGMT</i> hypermethylated glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 95-105. | 1.2 | 100 |
| 154 | Prognostic significance of IDH-1 and <i>MGMT</i> in patients with glioblastoma: One step forward, and one step back?. <i>Radiation Oncology</i> , 2011, 6, 115. | 2.7 | 99 |
| 155 | Emerging intersections between neuroscience and glioma biology. <i>Nature Neuroscience</i> , 2019, 22, 1951-1960. | 14.8 | 99 |
| 156 | The Potential of Relaxation-Weighted Sodium Magnetic Resonance Imaging as Demonstrated on Brain Tumors. <i>Investigative Radiology</i> , 2011, 46, 539-547. | 6.2 | 98 |
| 157 | Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. <i>Acta Oncologica</i> , 2013, 52, 147-152. | 1.8 | 98 |
| 158 | No Signal Intensity Increase in the Dentate Nucleus on Unenhanced T1-weighted MR Images after More than 20 Serial Injections of Macrocyclic Gadolinium-based Contrast Agents. <i>Radiology</i> , 2017, 282, 699-707. | 7.3 | 98 |
| 159 | Tryptophan degradation in autoimmune diseases. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 2542-2563. | 5.4 | 95 |
| 160 | Can Virtual Contrast Enhancement in Brain MRI Replace Gadolinium?. <i>Investigative Radiology</i> , 2019, 54, 653-660. | 6.2 | 93 |
| 161 | Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852. | 1.6 | 93 |
| 162 | Rechallenge with temozolomide in patients with recurrent gliomas. <i>Journal of Neurology</i> , 2009, 256, 734-741. | 3.6 | 92 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | A malignant cellular network in gliomas: potential clinical implications. <i>Neuro-Oncology</i> , 2016, 18, 479-485. | 1.2 | 91 |
| 164 | Pseudoprogession in patients with glioblastoma: clinical relevance despite low incidence. <i>Neuro-Oncology</i> , 2015, 17, 151-159. | 1.2 | 90 |
| 165 | BCL-2 promotes migration and invasiveness of human glioma cells. <i>FEBS Letters</i> , 1998, 440, 419-424. | 2.8 | 89 |
| 166 | Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. <i>Glia</i> , 2003, 42, 379-389. | 4.9 | 89 |
| 167 | Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1139-1147. | 1.2 | 89 |
| 168 | Malignant Glioma Cells Counteract Antitumor Immune Responses through Expression of Lectin-Like Transcript-1. <i>Cancer Research</i> , 2007, 67, 3540-3544. | 0.9 | 87 |
| 169 | In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13227-13232. | 7.1 | 87 |
| 170 | VXM01 phase I study in patients with progressive glioblastoma: Final results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2017-2017. | 1.6 | 87 |
| 171 | Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor- β 2. <i>Journal of Neuroscience</i> , 2001, 21, 3360-3368. | 3.6 | 85 |
| 172 | Steroids in neurooncology: actions, indications, side-effects. <i>Current Opinion in Neurology</i> , 2010, 23, 597-602. | 3.6 | 85 |
| 173 | Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. <i>European Journal of Neurology</i> , 2022, 29, 555-563. | 3.3 | 85 |
| 174 | N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor- β release and reduces migration and invasiveness of human malignant glioma cells. <i>International Journal of Cancer</i> , 2001, 93, 53-61. | 5.1 | 84 |
| 175 | Evaluation of Microvascular Permeability with Dynamic Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: Radiologic-Pathologic Correlation. <i>American Journal of Neuroradiology</i> , 2014, 35, 1503-1508. | 2.4 | 84 |
| 176 | Gliomatosis cerebri: Molecular pathology and clinical course. <i>Annals of Neurology</i> , 2002, 52, 390-399. | 5.3 | 83 |
| 177 | Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial. <i>BMC Cancer</i> , 2010, 10, 478. | 2.6 | 83 |
| 178 | Inhibiting TGF- β 2 signaling restores immune surveillance in the SMA-560 glioma model. <i>Neuro-Oncology</i> , 2007, 9, 259-270. | 1.2 | 82 |
| 179 | Intraindividual Analysis of Signal Intensity Changes in the Dentate Nucleus After Consecutive Serial Applications of Linear and Macrocyclic Gadolinium-Based Contrast Agents. <i>Investigative Radiology</i> , 2016, 51, 683-690. | 6.2 | 82 |
| 180 | Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. <i>Journal of Neuroimmunology</i> , 2013, 265, 106-116. | 2.3 | 81 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 181 | Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. <i>Nature Communications</i> , 2021, 12, 1014. | 12.8 | 81 |
| 182 | Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. <i>Cancer Research</i> , 2002, 62, 1915-9. | 0.9 | 80 |
| 183 | Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. <i>Neuro-Oncology</i> , 2009, 11, 747-756. | 1.2 | 79 |
| 184 | Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. <i>Neuro-Oncology</i> , 2018, 20, 367-379. | 1.2 | 79 |
| 185 | Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. <i>Neuro-Oncology</i> , 2013, 15, 1017-1026. | 1.2 | 78 |
| 186 | Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. <i>Brain</i> , 2005, 128, 2200-2211. | 7.6 | 77 |
| 187 | Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , 2014, 16, 1630-1638. | 1.2 | 77 |
| 188 | Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. <i>Neuro-Oncology</i> , 2012, 14, 222-229. | 1.2 | 76 |
| 189 | The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018, 135, 601-615. | 7.7 | 76 |
| 190 | Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial. <i>BMC Cancer</i> , 2010, 10, 533. | 2.6 | 75 |
| 191 | A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . <i>Neuro-Oncology</i> , 2021, 23, 34-43. | 1.2 | 75 |
| 192 | A novel tool to analyze MRI recurrence patterns in glioblastoma. <i>Neuro-Oncology</i> , 2008, 10, 1019-1024. | 1.2 | 74 |
| 193 | Pediatric Brain: No Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-weighted MR Images after Consecutive Exposure to a Macrocyclic Gadolinium-based Contrast Agent. <i>Radiology</i> , 2017, 283, 828-836. | 7.3 | 74 |
| 194 | K27M-mutant histone-3 as a novel target for glioma immunotherapy. <i>Oncolmmunology</i> , 2017, 6, e1328340. | 4.6 | 74 |
| 195 | Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. <i>Acta Neuropathologica</i> , 2019, 138, 295-308. | 7.7 | 74 |
| 196 | Pirfenidone inhibits TGF- β 2 expression in malignant glioma cells. <i>Biochemical and Biophysical Research Communications</i> , 2007, 354, 542-547. | 2.1 | 72 |
| 197 | Synergistic antiglioma activity of radiotherapy and enzastaurin. <i>Annals of Neurology</i> , 2007, 61, 153-161. | 5.3 | 72 |
| 198 | T1-weighted Dynamic Glucose-enhanced MR Imaging in the Human Brain. <i>Radiology</i> , 2017, 285, 914-922. | 7.3 | 72 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 199 | Bevacizumab does not increase the risk of remote relapse in malignant glioma. <i>Annals of Neurology</i> , 2011, 69, 586-592. | 5.3 | 71 |
| 200 | Neurological sequelae of cancer immunotherapies and targeted therapies. <i>Lancet Oncology</i> , The, 2016, 17, e529-e541. | 10.7 | 71 |
| 201 | Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology. <i>Nature Communications</i> , 2019, 10, 4877. | 12.8 | 69 |
| 202 | Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1434-1441. | 1.2 | 68 |
| 203 | Integrated molecular characterization of IDH1 mutant glioblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 108-118. | 3.2 | 68 |
| 204 | No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 15-22. | 2.9 | 66 |
| 205 | Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019, 21, 837-853. | 1.2 | 66 |
| 206 | Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1248-1255. | 4.1 | 65 |
| 207 | Individualized Targeted Therapy for Glioblastoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 40-44. | 2.0 | 64 |
| 208 | Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250. | 1.2 | 64 |
| 209 | Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients. <i>European Radiology</i> , 2019, 29, 4957-4967. | 4.5 | 64 |
| 210 | SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. <i>Neuro-Oncology</i> , 2021, 23, 1835-1844. | 1.2 | 64 |
| 211 | S3 "Guideline "Diagnosis, therapy and follow-up of melanoma" short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 563-602. | 0.8 | 63 |
| 212 | cIMPACT NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22 27, 851-852. | 4.1 | 63 |
| 213 | Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. <i>Oncotarget</i> , 2018, 9, 28772-28783. | 1.8 | 63 |
| 214 | Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. <i>JCI Insight</i> , 2019, 4, . | 5.0 | 63 |
| 215 | Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. <i>Oncotarget</i> , 2016, 7, 15018-15032. | 1.8 | 62 |
| 216 | Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas. <i>Neuro-Oncology</i> , 2020, 22, 928-935. | 1.2 | 62 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Nuclear Overhauser Enhancement Mediated Chemical Exchange Saturation Transfer Imaging at 7 Tesla in Glioblastoma Patients. PLoS ONE, 2014, 9, e104181. | 2.5 | 62 |
| 218 | Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T ₁ - and T ₂ *-based bolus techniques. Journal of Magnetic Resonance Imaging, 2015, 42, 87-96. | 3.4 | 61 |
| 219 | Current status and future directions of anti-angiogenic therapy for gliomas. Neuro-Oncology, 2016, 18, 315-328. | 1.2 | 61 |
| 220 | Pharmacotherapy of Epileptic Seizures in Glioma Patients: Who, When, Why and How Long?. Oncology Research and Treatment, 2005, 28, 391-396. | 1.2 | 59 |
| 221 | Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375. | 1.2 | 59 |
| 222 | CODEL: phase III study of RT, RT+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-Oncology, 2021, 23, 457-467. | 1.2 | 58 |
| 223 | Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathologica, 2019, 138, 497-504. | 7.7 | 57 |
| 224 | Differentiation of glioblastoma and primary CNS lymphomas using susceptibility weighted imaging. European Journal of Radiology, 2013, 82, 552-556. | 2.6 | 56 |
| 225 | Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of IDH Mutation Status and Tumor Progression. American Journal of Neuroradiology, 2016, 37, 66-73. | 2.4 | 56 |
| 226 | Association of Blood Pressure With Short- and Long-Term Functional Outcome After Stroke Thrombectomy. Stroke, 2018, 49, 1451-1456. | 2.0 | 56 |
| 227 | Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro-Oncology, 2018, 20, 400-410. | 1.2 | 56 |
| 228 | Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro-Oncology, 2019, 21, 1587-1594. | 1.2 | 56 |
| 229 | TTFields: where does all the skepticism come from?. Neuro-Oncology, 2016, 18, 303-305. | 1.2 | 55 |
| 230 | Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: <i>in vitro</i> paradigm of differential neurotoxicity. Journal of Neurochemistry, 2004, 91, 1067-1074. | 3.9 | 54 |
| 231 | Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. Biochemical and Biophysical Research Communications, 2005, 328, 125-129. | 2.1 | 54 |
| 232 | Molecular predictors of outcome in low-grade glioma. Current Opinion in Neurology, 2012, 25, 767-773. | 3.6 | 54 |
| 233 | Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology, 2017, 88, 1422-1430. | 1.1 | 54 |
| 234 | Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography. Annals of Neurology, 2017, 82, 676-685. | 5.3 | 54 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 235 | Modulation of TGF β 2 activity by latent TGF β 2-binding protein 1 in human malignant glioma cells. <i>International Journal of Cancer</i> , 2009, 125, 530-540. | 5.1 | 53 |
| 236 | Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. <i>Neuro-Oncology</i> , 2013, 15, 1405-1412. | 1.2 | 53 |
| 237 | Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016, 18, 401-407. | 1.2 | 53 |
| 238 | Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. <i>Scientific Reports</i> , 2017, 7, 41271. | 3.3 | 53 |
| 239 | Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. <i>Journal of Neuro-Oncology</i> , 2014, 117, 141-145. | 2.9 | 52 |
| 240 | Concepts in glioma immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1269-1275. | 4.2 | 52 |
| 241 | Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. <i>Acta Neuropathologica</i> , 2021, 141, 85-100. | 7.7 | 52 |
| 242 | Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. <i>Oncotarget</i> , 2015, 6, 31050-31068. | 1.8 | 52 |
| 243 | Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , 2021, 3, e784-e794. | 12.3 | 52 |
| 244 | Microenvironmental Clues for Glioma Immunotherapy. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 440. | 4.2 | 51 |
| 245 | Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. <i>Glia</i> , 2015, 63, 78-90. | 4.9 | 51 |
| 246 | The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. <i>Oncolimmunology</i> , 2016, 5, e1240858. | 4.6 | 51 |
| 247 | MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma. <i>Radiology</i> , 2016, 279, 542-552. | 7.3 | 51 |
| 248 | Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 670-676. | 0.8 | 50 |
| 249 | Mouse Mesenchymal Stem Cells Suppress Antigen-Specific TH Cell Immunity Independent of Indoleamine 2,3-Dioxygenase 1 (IDO1). <i>Stem Cells and Development</i> , 2010, 19, 657-668. | 2.1 | 49 |
| 250 | Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 305-312. | 4.2 | 49 |
| 251 | Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology</i> , The, 2012, 13, e196-e204. | 10.7 | 49 |
| 252 | Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial. <i>BMC Cancer</i> , 2010, 10, 615. | 2.6 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 253 | Tryptophanâ€2,3â€dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptorâ€4. <i>Journal of Neurochemistry</i> , 2016, 136, 1142-1154. | 3.9 | 48 |
| 254 | Synaptic input to brain tumors: clinical implications. <i>Neuro-Oncology</i> , 2021, 23, 23-33. | 1.2 | 48 |
| 255 | How Lymphotoxic Is Dose-Intensified Temozolomide? The Glioblastoma Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 4235-4236. | 1.6 | 47 |
| 256 | Outcome and Prognostic Factors of Radiation Therapy for Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e7-e13. | 0.8 | 47 |
| 257 | KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas. <i>Brain</i> , 2012, 135, 1027-1041. | 7.6 | 47 |
| 258 | Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. <i>Journal of Neurochemistry</i> , 2014, 131, 251-264. | 3.9 | 47 |
| 259 | Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trialâ€”study protocol. <i>BMJ Open</i> , 2016, 6, e010956. | 1.9 | 46 |
| 260 | EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2001-2001. | 1.6 | 46 |
| 261 | Brain Edema in Neurooncology: Radiological Assessment and Management. <i>Oncology Research and Treatment</i> , 2004, 27, 261-266. | 1.2 | 45 |
| 262 | Harmful networks in the brain and beyond. <i>Science</i> , 2018, 359, 1100-1101. | 12.6 | 45 |
| 263 | Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1255-1268. | 3.8 | 45 |
| 264 | YAP1-fusions in pediatric NF2-wildtype meningioma. <i>Acta Neuropathologica</i> , 2020, 139, 215-218. | 7.7 | 45 |
| 265 | Infratentorial IDH-mutant astrocytoma is a distinct subtype. <i>Acta Neuropathologica</i> , 2020, 140, 569-581. | 7.7 | 45 |
| 266 | Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas. <i>Glia</i> , 2011, 59, 1200-1204. | 4.9 | 44 |
| 267 | The mTOR signaling pathway as a treatment target for intracranial neoplasms. <i>Neuro-Oncology</i> , 2015, 17, 189-199. | 1.2 | 44 |
| 268 | Cerebrospinal fluid proteomic profiling in nusinersenâ€treated patients with spinal muscular atrophy. <i>Journal of Neurochemistry</i> , 2020, 153, 650-661. | 3.9 | 44 |
| 269 | Disconnecting multicellular networks in brain tumours. <i>Nature Reviews Cancer</i> , 2022, 22, 481-491. | 28.4 | 44 |
| 270 | ACNU-based chemotherapy for recurrent glioma in the temozolomide era. <i>Journal of Neuro-Oncology</i> , 2009, 92, 45-48. | 2.9 | 43 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 271 | Protein kinase C β 2 as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 14735-14740. | 7.1 | 43 |
| 272 | Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 121, 373-380. | 2.9 | 43 |
| 273 | ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi17-vi18. | 1.2 | 43 |
| 274 | Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. <i>Acta Neuropathologica</i> , 2019, 137, 837-846. | 7.7 | 43 |
| 275 | BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. <i>Cell Death and Differentiation</i> , 2006, 13, 1156-1169. | 11.2 | 42 |
| 276 | Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. <i>Brain</i> , 2009, 132, 1509-1522. | 7.6 | 42 |
| 277 | APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. <i>Neuro-Oncology</i> , 2011, 13, 155-164. | 1.2 | 42 |
| 278 | Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. <i>Acta Neuropathologica</i> , 2019, 138, 827-835. | 7.7 | 42 |
| 279 | Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. <i>Clinical Cancer Research</i> , 2019, 25, 253-265. | 7.0 | 42 |
| 280 | Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. <i>Neuro-Oncology</i> , 2020, 22, 1162-1172. | 1.2 | 42 |
| 281 | Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase. <i>PLoS ONE</i> , 2012, 7, e47663. | 2.5 | 42 |
| 282 | P-glycoprotein and Multidrug Resistance-associated Protein Mediate Specific Patterns of Multidrug Resistance in Malignant Glioma Cell Lines, but not in Primary Glioma Cells. <i>Brain Pathology</i> , 2003, 13, 482-494. | 4.1 | 41 |
| 283 | Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. <i>Biochemical Pharmacology</i> , 2011, 82, 632-641. | 4.4 | 41 |
| 284 | Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2132-2145. | 3.8 | 41 |
| 285 | Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459. | | 41 |
| 286 | Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis. <i>ELife</i> , 2016, 5, e11712. | 6.0 | 40 |
| 287 | Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2016, 18, 1313-1318. | 1.2 | 39 |
| 288 | PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma. <i>Acta Dermato-Venereologica</i> , 2017, 97, 395-396. | 1.3 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps. PLoS ONE, 2017, 12, e0174620. | 2.5 | 39 |
| 290 | Temozolomide: a milestone in the pharmacotherapy of brain tumors. Future Oncology, 2005, 1, 747-754. | 2.4 | 38 |
| 291 | Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncologica, 2011, 50, 630-635. | 1.8 | 38 |
| 292 | Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-Oncology, 2016, 18, 991-1001. | 1.2 | 38 |
| 293 | Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro-Oncology, 2020, 22, 1568-1579. | 1.2 | 38 |
| 294 | Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC) | 1.6 | 38 |
| 295 | Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.. Journal of Clinical Oncology, 2019, 37, 2000-2000. | 1.6 | 38 |
| 296 | BCL-2-induced glioma cell invasiveness depends on furin-like proteases. Journal of Neurochemistry, 2004, 91, 1275-1283. | 3.9 | 37 |
| 297 | Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163. | 5.2 | 37 |
| 298 | Quantitative Dynamic Oxygen 17 MRI at 7.0 T for the Cerebral Oxygen Metabolism in Glioma. Radiology, 2020, 295, 181-189. | 7.3 | 37 |
| 299 | Modulation of MDR/MRP by wild-type and mutant p53. Journal of Clinical Investigation, 2001, 107, 643-645. | 8.2 | 37 |
| 300 | Nuclear Overhauser Enhancement Imaging of Glioblastoma at 7 Tesla: Region Specific Correlation with Apparent Diffusion Coefficient and Histology. PLoS ONE, 2015, 10, e0121220. | 2.5 | 36 |
| 301 | Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. Oncotarget, 2016, 7, 56713-56725. | 1.8 | 36 |
| 302 | Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Neuro-Oncology, 2016, 18, 1673-1679. | 1.2 | 36 |
| 303 | Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. Neuro-Oncology, 2018, 20, 1517-1524. | 1.2 | 36 |
| 304 | The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. Neuro-Oncology, 2022, 24, 213-225. | 1.2 | 36 |
| 305 | Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. Oncogene, 2013, 32, 1099-1109. | 5.9 | 35 |
| 306 | Understanding and Targeting Alkylator Resistance in Glioblastoma. Cancer Discovery, 2014, 4, 1120-1122. | 9.4 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , 2019, 21, 1447-1457. | 1.2 | 35 |
| 308 | Neuronal signatures in cancer. <i>International Journal of Cancer</i> , 2020, 147, 3281-3291. | 5.1 | 35 |
| 309 | Proximity ligation assay evaluates IDH1R132H presentation in gliomas. <i>Journal of Clinical Investigation</i> , 2015, 125, 593-606. | 8.2 | 35 |
| 310 | Automatic Analysis of Cellularity in Glioblastoma and Correlation with ADC Using Trajectory Analysis and Automatic Nuclei Counting. <i>PLoS ONE</i> , 2016, 11, e0160250. | 2.5 | 35 |
| 311 | Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021, 23, 1547-1559. | 1.2 | 34 |
| 312 | Adenoviral Natural Born Killer Gene Therapy for Malignant Glioma. <i>Human Gene Therapy</i> , 2003, 14, 1235-1246. | 2.7 | 33 |
| 313 | Glioblastoma in elderly patients: solid conclusions built on shifting sand?. <i>Neuro-Oncology</i> , 2018, 20, 174-183. | 1.2 | 33 |
| 314 | Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy. <i>Scientific Reports</i> , 2018, 8, 7201. | 3.3 | 33 |
| 315 | Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2723-2733. | 7.0 | 33 |
| 316 | Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839. | 7.7 | 33 |
| 317 | Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 485-494. | 4.3 | 32 |
| 318 | Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 995. | 4.1 | 32 |
| 319 | Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation in the NCT Neuro Master Match (N2M2) pilot study. <i>Neuro-Oncology</i> , 2018, 20, 826-837. | 1.2 | 32 |
| 320 | Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021, 141, 945-957. | 7.7 | 32 |
| 321 | Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT]) Tj ETQq1 1 0.784314 rgBT /Overbo 2001-2001. | 1.6 | 32 |
| 322 | Is there a role for benzodiazepines in the management of lumbar disc prolapse with acute sciatica?. <i>Pain</i> , 2010, 149, 470-475. | 4.2 | 31 |
| 323 | A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. <i>Journal of Neurology</i> , 2013, 260, 847-855. | 3.6 | 31 |
| 324 | Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. , 2015, 34, 313-321. | | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 325 | Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma. <i>BMC Cancer</i> , 2015, 15, 558. | 2.6 | 31 |
| 326 | Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model. <i>Blood</i> , 2021, 137, 1219-1232. | 1.4 | 31 |
| 327 | Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. <i>Acta Neuropathologica</i> , 2021, 141, 281-290. | 7.7 | 31 |
| 328 | Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. <i>Cancer</i> , 2001, 91, 423-427. | 4.1 | 30 |
| 329 | Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma. <i>BMC Cancer</i> , 2011, 11, 127. | 2.6 | 30 |
| 330 | Quantification of Tumor Vessels in Glioblastoma Patients Using Time-of-Flight Angiography at 7 Tesla: A Feasibility Study. <i>PLoS ONE</i> , 2014, 9, e110727. | 2.5 | 30 |
| 331 | Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM). <i>Theranostics</i> , 2020, 10, 1873-1883. | 10.0 | 30 |
| 332 | A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG) <i>Tj ETQq6 0 0 rgBT9/Overlock</i> | 4.0 | 30 |
| 333 | Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. <i>Acta Neuropathologica Communications</i> , 2018, 6, 21. | 5.2 | 28 |
| 334 | Anti-Angiogenics: Their Role in the Treatment of Glioblastoma. <i>Oncology Research and Treatment</i> , 2018, 41, 181-186. | 1.2 | 28 |
| 335 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated <i>O⁶-methylguanine-DNA methyltransferase (MGMT)</i> gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA2009-LBA2009. | 1.6 | 28 |
| 336 | Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. <i>Acta Neuropathologica Communications</i> , 2022, 10, 1. | 5.2 | 28 |
| 337 | Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study. <i>Journal of Neuro-Oncology</i> , 2002, 59, 151-155. | 2.9 | 27 |
| 338 | Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas. <i>European Neurology</i> , 2013, 69, 95-101. | 1.4 | 27 |
| 339 | Chemical exchange saturation transfer (CEST) signal intensity at 7T MRI of WHO IV ^o gliomas is dependent on the anatomic location. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 777-785. | 3.4 | 27 |
| 340 | T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa004. | 0.7 | 27 |
| 341 | Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research</i> , 2022, 28, 2527-2535. | 7.0 | 27 |
| 342 | Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. <i>Gene Therapy</i> , 2007, 14, 147-161. | 4.5 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 343 | Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL _{xL} . Journal of Neurochemistry, 2008, 106, 2436-2448. | 3.9 | 26 |
| 344 | Shaping the glioma immune microenvironment through tryptophan metabolism. CNS Oncology, 2012, 1, 99-106. | 3.0 | 26 |
| 345 | A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2020, 146, 79-89. | 2.9 | 26 |
| 346 | Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 2005-2005. | 1.6 | 26 |
| 347 | Geriatric neuro-oncology. Current Opinion in Neurology, 2011, 24, 599-604. | 3.6 | 25 |
| 348 | CMV infection and glioma, a highly controversial concept struggling in the clinical arena. Neuro-Oncology, 2014, 16, 332-333. | 1.2 | 25 |
| 349 | Infiltrative patterns of glioblastoma: Identification of tumor progress using apparent diffusion coefficient histograms. Journal of Magnetic Resonance Imaging, 2014, 39, 1096-1103. | 3.4 | 25 |
| 350 | Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. Molecular Cancer Research, 2018, 16, 767-776. | 3.4 | 25 |
| 351 | Tumor cell network integration in glioma represents a stemness feature. Neuro-Oncology, 2021, 23, 757-769. | 1.2 | 25 |
| 352 | Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro-Oncology, 2022, 24, 755-767. | 1.2 | 25 |
| 353 | Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathologica, 2004, 107, 17-22. | 7.7 | 24 |
| 354 | Mechanisms of Resistance of Human Glioma Cells to Apo2 Ligand/TNF-Related Apoptosis-Inducing Ligand. Cellular Physiology and Biochemistry, 2007, 20, 023-034. | 1.6 | 24 |
| 355 | Neuroradiological Response Criteria for High-grade Gliomas. Clinical Neuroradiology, 2011, 21, 199-205. | 1.9 | 24 |
| 356 | Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio. Neuro-Oncology, 2018, 20, 557-566. | 1.2 | 24 |
| 357 | Quantitative MR neurography biomarkers in 5q-linked spinal muscular atrophy. Neurology, 2019, 93, e653-e664. | 1.1 | 24 |
| 358 | Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBP β . Frontiers in Immunology, 2020, 11, 657. | 4.8 | 24 |
| 359 | TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro-Oncology, 2021, 23, 76-87. | 1.2 | 24 |
| 360 | Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. Acta Neuropathologica, 2021, 142, 179-189. | 7.7 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 361 | Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial. <i>British Journal of Cancer</i> , 2021, 125, 955-965. | 6.4 | 24 |
| 362 | Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. <i>Targeted Oncology</i> , 2010, 5, 183-191. | 3.6 | 23 |
| 363 | Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. <i>Future Oncology</i> , 2010, 6, 1407-1414. | 2.4 | 23 |
| 364 | Mutant IDH1: An immunotherapeutic target in tumors. <i>Oncolmmunology</i> , 2014, 3, e974392. | 4.6 | 23 |
| 365 | Chemotherapy for intracranial ependymoma in adults. <i>BMC Cancer</i> , 2016, 16, 287. | 2.6 | 23 |
| 366 | Suppression of Th1 differentiation by tryptophan supplementation in vivo. <i>Amino Acids</i> , 2017, 49, 1169-1175. | 2.7 | 23 |
| 367 | Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. <i>Neuro-Oncology</i> , 2023, 25, 263-276. | 1.2 | 23 |
| 368 | The aryl hydrocarbon receptor in tumor immunity. <i>Oncolmmunology</i> , 2012, 1, 396-397. | 4.6 | 22 |
| 369 | The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019, 116, 190-198. | 2.8 | 22 |
| 370 | German Cancer Consortium (DKTK) â€“ A national consortium for translational cancer research. <i>Molecular Oncology</i> , 2019, 13, 535-542. | 4.6 | 22 |
| 371 | Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs. <i>Molecular Cancer Research</i> , 2021, 19, 688-701. | 3.4 | 22 |
| 372 | A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 39-51. | 1.2 | 22 |
| 373 | Anticoagulation for radiation-induced neurotoxicity revisited. <i>Journal of Neuro-Oncology</i> , 2008, 90, 357-362. | 2.9 | 21 |
| 374 | VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. <i>Brain</i> , 2008, 131, 2579-2595. | 7.6 | 21 |
| 375 | Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <i>Neuro-Oncology</i> , 2015, 17, vii32-vii40. | 1.2 | 21 |
| 376 | General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. <i>Journal of Neuroimmunology</i> , 2016, 297, 117-126. | 2.3 | 21 |
| 377 | Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 126, 463-472. | 2.9 | 21 |
| 378 | A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2001-2001. | 1.6 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 379 | Prognostic relevance of miRNA-155 methylation in anaplastic glioma. <i>Oncotarget</i> , 2016, 7, 82028-82045. | 1.8 | 21 |
| 380 | N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon- β (IFN- β). <i>British Journal of Pharmacology</i> , 2001, 134, 1279-1284. | 5.4 | 20 |
| 381 | Improving outcome in newly diagnosed malignant glioma. <i>Nature Reviews Neurology</i> , 2014, 10, 68-70. | 10.1 | 20 |
| 382 | Cortical vessel sign on susceptibility weighted imaging reveals clinically relevant hypoperfusion in internal carotid artery stenosis. <i>European Journal of Radiology</i> , 2016, 85, 534-539. | 2.6 | 20 |
| 383 | Sequential proton boost after standard chemoradiation for high-grade glioma. <i>Radiotherapy and Oncology</i> , 2017, 125, 266-272. | 0.6 | 20 |
| 384 | Current usage of tumor treating fields for glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa069. | 0.7 | 20 |
| 385 | Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA2000-LBA2000. | 1.6 | 20 |
| 386 | Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. <i>Journal of Neuro-Oncology</i> , 2010, 97, 157-158. | 2.9 | 19 |
| 387 | NDRG1 prognosticates the natural course of disease in WHO grade II glioma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 25-32. | 2.9 | 19 |
| 388 | New glioblastoma heterogeneity atlas "a shared resource. <i>Nature Reviews Neurology</i> , 2018, 14, 453-454. | 10.1 | 19 |
| 389 | Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e480. | 6.0 | 19 |
| 390 | Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020, 9, 8373-8385. | 2.8 | 19 |
| 391 | Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020, 297, 164-175. | 7.3 | 19 |
| 392 | Determining medical decision-making capacity in brain tumor patients: why and how?. <i>Neuro-Oncology Practice</i> , 2020, 7, 599-612. | 1.6 | 19 |
| 393 | Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. <i>Acta Neuropathologica</i> , 2022, 143, 609-612. | 7.7 | 19 |
| 394 | A prospective trial of mechanical physiotherapy for lumbar disk prolapse. <i>Journal of Neurology</i> , 2003, 250, 746-749. | 3.6 | 18 |
| 395 | Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T cell-mediated killing of glioblastoma cells <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2005, 117, 1060-1064. | 5.1 | 18 |
| 396 | De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 299-307. | 3.2 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 397 | Quantitative and qualitative analysis of study-related patient information sheets in randomised neuro-oncology phase III-trials. <i>European Journal of Cancer</i> , 2014, 50, 150-158. | 2.8 | 18 |
| 398 | Treatment of Anaplastic Glioma. <i>Cancer Treatment and Research</i> , 2015, 163, 89-101. | 0.5 | 18 |
| 399 | Virtual Raters for Reproducible and Objective Assessments in Radiology. <i>Scientific Reports</i> , 2016, 6, 25007. | 3.3 | 18 |
| 400 | NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment. <i>Cancer Letters</i> , 2016, 380, 568-576. | 7.2 | 18 |
| 401 | Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. <i>Journal of Neurology</i> , 2017, 264, 341-349. | 3.6 | 18 |
| 402 | Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. <i>Current Opinion in Oncology</i> , 2018, 30, 368-374. | 2.4 | 18 |
| 403 | Understanding and Treating Glioblastoma. <i>Neurologic Clinics</i> , 2018, 36, 485-499. | 1.8 | 18 |
| 404 | Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. <i>European Journal of Cancer</i> , 2019, 114, 89-96. | 2.8 | 18 |
| 405 | Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 326-336. | 1.2 | 18 |
| 406 | Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1742-1756. | 1.2 | 18 |
| 407 | Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. <i>Journal of Neurochemistry</i> , 2021, 158, 522-538. | 3.9 | 18 |
| 408 | Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2002-2002. | 1.6 | 18 |
| 409 | Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach?. <i>Discovery Medicine</i> , 2011, 11, 529-36. | 0.5 | 18 |
| 410 | Oligosarcomas, IDH-mutant are distinct and aggressive. <i>Acta Neuropathologica</i> , 2022, 143, 263-281. | 7.7 | 18 |
| 411 | Glioblastoma in the elderly: making sense of the evidence. <i>Neuro-Oncology Practice</i> , 2016, 3, 77-86. | 1.6 | 17 |
| 412 | First results on the DCVax phase III trial: raising more questions than providing answers. <i>Neuro-Oncology</i> , 2018, 20, 1283-1284. | 1.2 | 17 |
| 413 | GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2000-2000. | 1.6 | 17 |
| 414 | Intracranial Metastatic Esthesioneuroblastoma Responsive to Temozolomide. <i>Journal of Neuro-Oncology</i> , 2004, 70, 73-75. | 2.9 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 415 | Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept. <i>BMC Cancer</i> , 2010, 10, 450. | 2.6 | 16 |
| 416 | Advances in malignant glioma drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 739-753. | 5.0 | 16 |
| 417 | Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies. <i>Current Treatment Options in Oncology</i> , 2013, 14, 505-513. | 3.0 | 16 |
| 418 | Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neovascularization in Preclinical Models and Human Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 1004. | 2.8 | 16 |
| 419 | Automated volumetric assessment with artificial neural networks might enable a more accurate assessment of disease burden in patients with multiple sclerosis. <i>European Radiology</i> , 2020, 30, 2356-2364. | 4.5 | 16 |
| 420 | GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. <i>Acta Neuropathologica</i> , 2021, 142, 1065-1069. | 7.7 | 16 |
| 421 | Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. <i>Theranostics</i> , 2021, 11, 9217-9233. | 10.0 | 16 |
| 422 | Capillary Transit Time Heterogeneity Is Associated with Modified Rankin Scale Score at Discharge in Patients with Bilateral High Grade Internal Carotid Artery Stenosis. <i>PLoS ONE</i> , 2016, 11, e0158148. | 2.5 | 16 |
| 423 | Regulation of pulmonary <i>Pseudomonas aeruginosa</i> infection by the transcriptional repressor Gfi1. <i>Cellular Microbiology</i> , 2006, 8, 1096-1105. | 2.1 | 15 |
| 424 | Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. <i>Neuro-Oncology</i> , 2018, 20, 1525-1535. | 1.2 | 15 |
| 425 | Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 637-648. | 3.3 | 15 |
| 426 | Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. <i>Frontiers in Oncology</i> , 2021, 11, 636672. | 2.8 | 15 |
| 427 | Deciphering the Systems Biology of mTOR Inhibition by Integrative Transcriptome Analysis. <i>Current Pharmaceutical Design</i> , 2014, 20, 88-100. | 1.9 | 15 |
| 428 | Defective p53 antiangiogenic signaling in glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 894-907. | 1.2 | 14 |
| 429 | Outcome of patients with proximal vessel occlusion of the anterior circulation and DWI-PWI mismatch is time-dependent. <i>European Journal of Radiology</i> , 2017, 91, 82-87. | 2.6 | 14 |
| 430 | A PRDX1-p38 β heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas. <i>International Journal of Cancer</i> , 2018, 143, 1176-1187. | 5.1 | 14 |
| 431 | Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 659-670. | 2.5 | 14 |
| 432 | Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee. <i>BMC Cancer</i> , 2020, 20, 410. | 2.6 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 433 | Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa038. | 0.7 | 14 |
| 434 | Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2020, 149, 65-71. | 2.9 | 14 |
| 435 | Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2019-2019. | 1.6 | 14 |
| 436 | Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2020. | 1.6 | 14 |
| 437 | Differential Expression of Egr1 and Activation of Microglia Following Irradiation in the Rat Brain. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 248-255. | 2.0 | 13 |
| 438 | RTOG 9802: Good Wines Need Aging. <i>Journal of Clinical Oncology</i> , 2013, 31, 653-654. | 1.6 | 13 |
| 439 | Tunneling nanotube-like structures in brain tumors. <i>Cancer Reports</i> , 2019, 2, . | 1.4 | 13 |
| 440 | Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 201. | 5.2 | 13 |
| 441 | LAPTM5-CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 747. | 2.8 | 13 |
| 442 | Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?. <i>Journal of Neuro-Oncology</i> , 2021, 152, 483-490. | 2.9 | 13 |
| 443 | Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2003-2003. | 1.6 | 13 |
| 444 | Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2007-2007. | 1.6 | 13 |
| 445 | Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1533-1545. | 1.2 | 13 |
| 446 | AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. <i>Neurological Research and Practice</i> , 2022, 4, . | 2.0 | 13 |
| 447 | Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , 2017, 133, 325-327. | 7.7 | 12 |
| 448 | Vaccine Strategies in Gliomas. <i>Current Treatment Options in Neurology</i> , 2018, 20, 11. | 1.8 | 12 |
| 449 | The KEEP SIMPLEST Study: Improving In-House Delays and Periinterventional Management in Stroke Thrombectomy—A Matched Pair Analysis. <i>Neurocritical Care</i> , 2019, 31, 46-55. | 2.4 | 12 |
| 450 | cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 9-23. | 2.9 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 451 | Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 117-130. | 2.9 | 12 |
| 452 | Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials. <i>European Journal of Cancer</i> , 2021, 144, 162-168. | 2.8 | 12 |
| 453 | Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. <i>Acta Neuropathologica Communications</i> , 2022, 10, 5. | 5.2 | 12 |
| 454 | Classification and management of anaplastic gliomas. <i>Current Opinion in Neurology</i> , 2009, 22, 650-656. | 3.6 | 11 |
| 455 | Trabedersen to target transforming growth factor- β : when the journey is not the reward, in reference to Bogdahn et al. (<i>Neuro-Oncology</i> 2011;13:132-142). <i>Neuro-Oncology</i> , 2011, 13, 559-560. | 1.2 | 11 |
| 456 | Differential Expression of the Tumor Suppressor A-Kinase Anchor Protein 12 in Human Diffuse and Pilocytic Astrocytomas Is Regulated by Promoter Methylation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 933-941. | 1.7 | 11 |
| 457 | Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 85-92. | 2.9 | 11 |
| 458 | Astrocytic gliomas WHO grades II and III. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 345-360. | 1.8 | 11 |
| 459 | Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas. <i>Cancer</i> , 2018, 124, 2674-2676. | 4.1 | 11 |
| 460 | Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978. | 7.7 | 11 |
| 461 | Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , 2018, 101, 95-104. | 2.8 | 11 |
| 462 | Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2019, 145, 531-540. | 2.9 | 11 |
| 463 | Susceptibility-weighted imaging in malignant melanoma brain metastasis. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1251-1259. | 3.4 | 11 |
| 464 | Adult precision medicine: learning from the past to enhance the future. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa145. | 0.7 | 11 |
| 465 | T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas. <i>Clinical Cancer Research</i> , 2022, 28, 378-389. | 7.0 | 11 |
| 466 | Treosulfan chemotherapy for recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2000, 49, 231-234. | 2.9 | 10 |
| 467 | No preferential loss of paternal 19q alleles in oligodendroglial tumors. <i>Annals of Neurology</i> , 2003, 54, 256-258. | 5.3 | 10 |
| 468 | Glioma tropism of lentivirally transduced hematopoietic progenitor cells. <i>International Journal of Oncology</i> , 2010, 36, 1409-17. | 3.3 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 469 | Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). <i>Journal of Neuro-Oncology</i> , 2011, 104, 801-809. | 2.9 | 10 |
| 470 | Challenging cytomegalovirus data in glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 165-165. | 1.2 | 10 |
| 471 | Examining cognitive emotion regulation inÂfrontal lobe patients: The mediating role ofÂresponse inhibition. <i>NeuroRehabilitation</i> , 2015, 37, 89-98. | 1.3 | 10 |
| 472 | Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 41, 0271678X2096185. | 4.3 | 10 |
| 473 | Individualized blood pressure management during endovascular treatment of acute ischemic stroke under procedural sedation (INDIVIDUATE) â€“ An explorative randomized controlled trial. <i>European Stroke Journal</i> , 2021, 6, 276-282. | 5.5 | 10 |
| 474 | Telomerase reverse transcriptase promoter mutationâ€“ and O6-methylguanine DNA methyltransferase promoter methylationâ€“mediated sensitivity to temozolomide in isocitrate dehydrogenaseâ€“wild-type glioblastoma: is there a link?. <i>European Journal of Cancer</i> , 2021, 147, 84-94. | 2.8 | 10 |
| 475 | Radioresistance and Transcriptional Reprograming of Invasive Glioblastoma Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 499-513. | 0.8 | 10 |
| 476 | Bloodâ€“brain barrier and brain edema. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 53-62. | 1.8 | 9 |
| 477 | Good maths is needed to understand CMV data in glioblastoma. <i>International Journal of Cancer</i> , 2014, 134, 2991-2992. | 5.1 | 9 |
| 478 | Drug Repositioning Meets Precision in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 256-258. | 7.0 | 9 |
| 479 | Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019, 92, e2754-e2763. | 1.1 | 9 |
| 480 | Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. <i>Acta Neuropathologica</i> , 2020, 139, 403-406. | 7.7 | 9 |
| 481 | Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2020, 22, 1667-1676. | 1.2 | 9 |
| 482 | Oncolytic virotherapy: Potentially a game-changing tumor treatment. <i>Cancer Cell</i> , 2021, 39, 753-755. | 16.8 | 9 |
| 483 | Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2023-2023. | 1.6 | 9 |
| 484 | Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ÂŸ) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2061-2061. | 1.6 | 9 |
| 485 | Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2001-2001. | 1.6 | 9 |
| 486 | Genetically Modified Cellular Therapies for Malignant Gliomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12810. | 4.1 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 487 | Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma?. Neuro-Oncology, 2011, 13, 365-366. | 1.2 | 8 |
| 488 | Posterior Circulation Acute Stroke Prognosis Early Computed Tomography Score Using Hypointense Vessels on Susceptibility Weighted Imaging Independently Predicts Outcome in Patients with Basilar Artery Occlusion. PLoS ONE, 2015, 10, e0132587. | 2.5 | 8 |
| 489 | Toxicity of terflunomide in aryl hydrocarbon receptor deficient mice. Biochemical Pharmacology, 2015, 98, 484-492. | 4.4 | 8 |
| 490 | Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neuro-Oncology Advances, 2020, 2, vdz060. | 0.7 | 8 |
| 491 | Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23. Cancers, 2021, 13, 3451. | 3.7 | 8 |
| 492 | Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion. Journal of Clinical Oncology, 2017, 35, 2009-2009. | 1.6 | 8 |
| 493 | ¹ H-NMR-based metabolic profiling identifies non-invasive diagnostic and predictive urinary fingerprints in 5q spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2021, 16, 441. | 2.7 | 8 |
| 494 | Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial. Neuro-Oncology Advances, 2021, 3, vdab153. | 0.7 | 8 |
| 495 | <i>MEOX2</i> homeobox gene promotes growth of malignant gliomas. Neuro-Oncology, 2022, 24, 1911-1924. | 1.2 | 8 |
| 496 | Incidence, molecular characteristics, and imaging features of clinically-defined pseudoprogression in newly diagnosed glioblastoma treated with chemoradiation. Journal of Neuro-Oncology, 2022, 159, 509-518. | 2.9 | 8 |
| 497 | Perfusion Magnetic Resonance Imaging for Parametric Response Maps in Tumors: Is It Really That Easy?. Journal of Clinical Oncology, 2010, 28, e591-e591. | 1.6 | 7 |
| 498 | Malignant astrocytoma in elderly patients. Current Opinion in Neurology, 2013, 26, 693-700. | 3.6 | 7 |
| 499 | Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma. Cancers, 2019, 11, 314. | 3.7 | 7 |
| 500 | APG101_CD_002: A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma. Journal of Clinical Oncology, 2012, 30, 2034-2034. | 1.6 | 7 |
| 501 | Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. Neuro-Oncology Practice, 2022, 9, 310-316. | 1.6 | 7 |
| 502 | Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. Neuro-Oncology, 2022, 24, 2159-2169. | 1.2 | 7 |
| 503 | Role of TGF- β in oncogenesis. Microscopy Research and Technique, 2001, 52, 353-353. | 2.2 | 6 |
| 504 | Complete Resection of Contrast-Enhancing Tumor Volume is Associated With Improved Survival in Recurrent Glioblastoma Results From the DIRECTOR Trial. Neurosurgery, 2015, 62, 209. | 1.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 505 | Normal mast cell numbers in the tissues of AhR-deficient mice. <i>Experimental Dermatology</i> , 2016, 25, 62-63. | 2.9 | 6 |
| 506 | “But it's a nice compromise” Qualitative multicentre study of barriers and facilitators to acute telestroke cooperation in a regional stroke network. <i>European Journal of Neurology</i> , 2022, 29, 208-216. | 3.3 | 6 |
| 507 | MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 2015-2015. | 1.6 | 6 |
| 508 | A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16). <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2082-TPS2082. | 1.6 | 6 |
| 509 | Assessment of Sodium MRI at 7 Tesla as Predictor of Therapy Response and Survival in Glioblastoma Patients. <i>Frontiers in Neuroscience</i> , 2021, 15, 782516. | 2.8 | 6 |
| 510 | Glioblastoma: What's ischemia got to do with it?. <i>Neurology</i> , 2006, 67, 1540-1541. | 1.1 | 5 |
| 511 | Anaplastic gliomas: an emerging entity. <i>European Journal of Cancer</i> , 2011, 47, S357-S358. | 2.8 | 5 |
| 512 | Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 533-539. | 2.9 | 5 |
| 513 | Evidence-based management of adult patients with diffuse glioma “ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e430-e431. | 10.7 | 5 |
| 514 | Go, no-go decision making for phase 3 clinical trials: ACT IV revisited “ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e709-e710. | 10.7 | 5 |
| 515 | Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1472-1480. | 0.8 | 5 |
| 516 | ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION. <i>Neuro-Oncology</i> , 2019, 21, vi14-vi14. | 1.2 | 5 |
| 517 | Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. <i>Neuro-Oncology Practice</i> , 2020, 7, 668-675. | 1.6 | 5 |
| 518 | Primary CNS lymphoma after CLIPPERS: a case series. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1348-1349. | 1.9 | 5 |
| 519 | A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2014-2014. | 1.6 | 5 |
| 520 | DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma. <i>Acta Neuropathologica</i> , 2022, 144, 129-142. | 7.7 | 5 |
| 521 | The aryl hydrocarbon receptor as a promoter of malignant glioma. <i>Cell Cycle</i> , 2012, 11, 643-644. | 2.6 | 4 |
| 522 | Tregs in gliomas - the jury is still out. <i>Neuro-Oncology</i> , 2015, 17, 769-770. | 1.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 523 | Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2960. | 4.1 | 4 |
| 524 | PD1 and PD-L1 expression in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2011-2011. | 1.6 | 4 |
| 525 | Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N ² M ²).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2084-TPS2084. | 1.6 | 4 |
| 526 | VXM01 phase I study in patients with resectable progression of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2061-2061. | 1.6 | 4 |
| 527 | Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2041-2041. | 1.6 | 4 |
| 528 | HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. <i>Neuro-Oncology</i> , 2022, , . | 1.2 | 4 |
| 529 | AAMP is a binding partner of costimulatory human B7-H3. <i>Neuro-Oncology Advances</i> , 2022, 4, . | 0.7 | 4 |
| 530 | Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years. <i>Journal of Neuro-Oncology</i> , 2006, 77, 219-220. | 2.9 | 3 |
| 531 | Time-dependent parameter of perfusion imaging as independent predictor of clinical outcome in symptomatic carotid artery stenosis. <i>BMC Neurology</i> , 2016, 16, 50. | 1.8 | 3 |
| 532 | Increased Delay Between Gadolinium Chelate Administration and T1-Weighted Magnetic Resonance Imaging Acquisition Increases Contrast-Enhancing Tumor Volumes and T1 Intensities in Brain Tumor Patients. <i>Investigative Radiology</i> , 2018, 53, 223-228. | 6.2 | 3 |
| 533 | BSCI-11. Targeting PI3K/Akt/mTOR pathway to prevent melanoma brain metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, iii3-iii3. | 0.7 | 3 |
| 534 | MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2000-2000. | 1.6 | 3 |
| 535 | Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2017-2017. | 1.6 | 3 |
| 536 | Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2051-2051. | 1.6 | 3 |
| 537 | Residual tumor volume and change in tumor volume during adjuvant therapy to predict long-term survival in AVAglio: Phase 3 newly diagnosed glioblastoma patients treated with radiation, temozolomide, and bevacizumab or placebo.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2021-2021. | 1.6 | 3 |
| 538 | Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2012-2012. | 1.6 | 3 |
| 539 | Carbon ion reirradiation for patients with malignant gliomas: Toxicity and first results of the prospective dose-escalation phase I/II CINDERELLA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2059-2059. | 1.6 | 3 |
| 540 | Lumbar disk prolapse: response to mechanical physiotherapy in the absence of changes in magnetic resonance imaging. Report of 11 cases. <i>NeuroRehabilitation</i> , 2008, 23, 289-94. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 541 | Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac051. | 0.7 | 3 |
| 542 | Reply to F. Felix et al and M.F. Fay et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3107-3108. | 1.6 | 2 |
| 543 | Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. <i>Public Health Genomics</i> , 2016, 19, 170-177. | 1.0 | 2 |
| 544 | Not Yet Another Negative Trial—ReACTing on Recent Glioblastoma Trials. <i>Clinical Cancer Research</i> , 2020, 26, 1535-1537. | 7.0 | 2 |
| 545 | Adjuvant Therapy. <i>Recent Results in Cancer Research</i> , 2009, 171, 141-153. | 1.8 | 2 |
| 546 | Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF- β) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2039-2039. | 1.6 | 2 |
| 547 | Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2006-2006. | 1.6 | 2 |
| 548 | Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2057-2057. | 1.6 | 2 |
| 549 | Patient Pathways During Acute in-Hospital Stroke Treatment: A Qualitative Multi-Method Study. <i>International Journal of Integrated Care</i> , 2022, 22, 16. | 0.2 | 2 |
| 550 | Quantitative magnetic resonance neurographic characterization of peripheral nerve involvement in manifest and preataxic spinocerebellar ataxia type 3. <i>European Journal of Neurology</i> , 2022, , . | 3.3 | 2 |
| 551 | Lung toxicity of CCNU in the treatment of progressive gliomas. <i>Neuro-Oncology Advances</i> , 0, , . | 0.7 | 2 |
| 552 | Deep Learning Super-resolution MR Spectroscopic Imaging of Brain Metabolism and Mutant IDH Glioma. <i>Neuro-Oncology Advances</i> , 0, , . | 0.7 | 2 |
| 553 | “Nanomania” ante portas of neurooncology?. <i>Journal of Neuro-Oncology</i> , 2011, 104, 613-614. | 2.9 | 1 |
| 554 | mTORC 2:1 for Chemotherapy Sensitization in Glioblastoma: Figure 1.. <i>Cancer Discovery</i> , 2011, 1, 475-476. | 9.4 | 1 |
| 555 | Elderly people with glioblastoma “ Authors' reply. <i>Lancet Oncology</i> , The, 2012, 13, e329. | 10.7 | 1 |
| 556 | Gadofluorine M enhanced MRI in experimental glioma: Superior and persistent intracellular tumor enhancement compared with conventional MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 551-560. | 3.4 | 1 |
| 557 | Dietary tryptophan is required for CNS infiltration of encephalitogenic T cells. <i>Journal of Neuroimmunology</i> , 2014, 275, 156. | 2.3 | 1 |
| 558 | Reply to T.J. Kruser et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1282-1283. | 1.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 559 | Highlights in Central Nervous System Tumors. JAMA Oncology, 2016, 2, 1535. | 7.1 | 1 |
| 560 | What's New in Grade II and Grade III Gliomas?. Seminars in Neurology, 2018, 38, 041-049. | 1.4 | 1 |
| 561 | Steroid-Responsive Relapsing-Remitting Neutrophilic Encephalitis: A Case Report. Journal of Neuropathology and Experimental Neurology, 2018, 77, 993-996. | 1.7 | 1 |
| 562 | GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION. Neuro-Oncology, 2019, 21, ii83-ii83. | 1.2 | 1 |
| 563 | Continuous-Time Deep Glioma Growth Models. Lecture Notes in Computer Science, 2021, , 83-92. | 1.3 | 1 |
| 564 | Comparative evaluation of T cell receptors in experimental glioma-draining lymph nodes. Neuro-Oncology Advances, 2021, 3, vdab147. | 0.7 | 1 |
| 565 | Abstract 1308A: Novel antiinvasive and antiangiogenic mechanisms of mTOR inhibition in glioblastoma. , 2010, , . | | 1 |
| 566 | Abstract LB-382: Inhibition of CD95 signalling by APG-101 enhances efficacy of radiotherapy (RT) and reduces RT-induced tumor satellite formation. , 2011, , . | | 1 |
| 567 | Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.. Journal of Clinical Oncology, 2019, 37, 2022-2022. | 1.6 | 1 |
| 568 | Abstract LB-80: ATRX loss refines the classification of anaplastic glioma and is a favorable prognostic marker.. , 2013, , . | | 1 |
| 569 | Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab <i>plus</i> radiotherapy <i>plus</i> temozolomide for patients with newly diagnosed glioblastoma (AVAglio).. Journal of Clinical Oncology, 2016, 34, 2048-2048. | 1.6 | 1 |
| 570 | Abstract 464: Methylation of a single CpG site in the CD95-ligand promoter is a biomarker predicting the response to therapy with APG101 in glioblastoma. , 2016, , . | | 1 |
| 571 | Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, e14070-e14070. | 1.6 | 1 |
| 572 | Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. Neuro-Oncology Advances, 2020, 2, vdaa147. | 0.7 | 1 |
| 573 | Emergency intubation during thrombectomy for acute ischemic stroke in patients under primary procedural sedation. Neurological Research and Practice, 2021, 3, 27. | 2.0 | 1 |
| 574 | CSIG-18. CALCIUM COMMUNICATION IN GLIOMA: CRUCIAL PACEMAKER CELLS GOVERN TUMOR PROGRESSION. Neuro-Oncology, 2020, 22, ii31-ii31. | 1.2 | 1 |
| 575 | Gender disparity regarding work-life balance satisfaction among German neuro-oncologists: a YoungNOA survey. Neuro-Oncology, 2022, 24, 1609-1611. | 1.2 | 1 |
| 576 | Progression Patterns in Non-Contrast-Enhancing Gliomas Support Brain Tumor Responsiveness to Surgical Lesions. Pathology and Oncology Research, 0, 28, . | 1.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 577 | Reply to Lorenz et al.: Osteoprotegerin in the central nervous system. <i>Acta Neuropathologica</i> , 2004, 107, 578-578. | 7.7 | 0 |
| 578 | Molekular definierte Chemotherapien und zielgerichtete Therapien bei malignen Gliomen. <i>Onkopipeline</i> , 2008, 1, 11-16. | 0.0 | 0 |
| 579 | Therapie primärer ZNS-Lymphome. <i>Onkopipeline</i> , 2009, 2, 2-10. | 0.0 | 0 |
| 580 | Validation of Prognostic Significance of IDH1 and MGMT in Patients with Glioblastoma: One Step Forward, and One Step Back?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, S9-S10. | 0.8 | 0 |
| 581 | EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. <i>European Journal of Cancer</i> , Supplement, 2012, 10, 20-26. | 2.2 | 0 |
| 582 | The Addition of Bevacizumab (BEV) to Temozolomide (TMZ) and Radiation Therapy (RT) in Newly Diagnosed Glioblastoma (GBM) Improves Progression-Free Survival (PFS) Without Adding to RT Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S16. | 0.8 | 0 |
| 583 | In situ proximity ligation assay to evaluate presentation of a mutated CD4 epitope in human glioma tissue. <i>Journal of Neuroimmunology</i> , 2014, 275, 35. | 2.3 | 0 |
| 584 | Tryptophan-2,3-dioxygenase in experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2014, 275, 65. | 2.3 | 0 |
| 585 | Mutant IDH1R132H bears a mutation-specific CD4 T cell epitope suitable for vaccination of human CNS tumors. <i>Journal of Neuroimmunology</i> , 2014, 275, 39. | 2.3 | 0 |
| 586 | Impaired remission from autoimmune neuroinflammation upon T cell-specific knockout of the stress kinase GCN2. <i>Journal of Neuroimmunology</i> , 2014, 275, 174. | 2.3 | 0 |
| 587 | UV irradiation-mediated systemic immune suppression through AHR signalling. <i>Journal of Neuroimmunology</i> , 2014, 275, 128-129. | 2.3 | 0 |
| 588 | ANGI-08RADIOGENOMIC rCBV-IMAGING VISUALIZES THE DISTINCT ANGIOGENESIS TRANSCRIPTOME SIGNATURES OF IDH MUTANT AND WILD-TYPE GLIOMAS. <i>Neuro-Oncology</i> , 2015, 17, v42.3-v42. | 1.2 | 0 |
| 589 | Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 764-765. | 1.2 | 0 |
| 590 | NIMG-31. RESIDUAL ENHANCING TUMOR VOLUME IS A STRONG PROGNOSTIC BIOMARKER FOR SURVIVAL IN BOTH NEWLY DIAGNOSED AND RECURRENT GBM REGARDLESS OF THERAPY: EVIDENCE FROM 1,535 PATIENTS IN SINGLE AND MULTICENTER TRIALS. <i>Neuro-Oncology</i> , 2016, 18, vi131-vi131. | 1.2 | 0 |
| 591 | <i>Neuro-Oncology. Seminars in Neurology</i> , 2018, 38, 003-004. | 1.4 | 0 |
| 592 | IMMU-26. VISUALIZING TUMOR CELL - LYMPHOCYTE INTERACTIONS IN THE BRAIN METASTATIC CASCADE USING IN VIVO TWO PHOTON MICROSCOPY. <i>Neuro-Oncology</i> , 2018, 20, vi126-vi127. | 1.2 | 0 |
| 593 | ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi25-vi25. | 1.2 | 0 |
| 594 | ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIO THERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi14-vi14. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 595 | DDIS-17. MULTI-LEVEL DRUG DEVELOPMENT PIPELINE FOR THE DISCOVERY OF TUMOR MICROTUBE TARGETING DRUGS. <i>Neuro-Oncology</i> , 2018, 20, vi72-vi72. | 1.2 | 0 |
| 596 | Highlights of the inaugural ten "the launch of <i>Neuro-Oncology Advances</i> . <i>Neuro-Oncology Advances</i> , 2019, 1, vdz016. | 0.7 | 0 |
| 597 | Kindliche Hirntumoren bei Erwachsenen: Medulloblastom. <i>Springer Reference Medizin</i> , 2021, , 1-8. | 0.0 | 0 |
| 598 | Abstract 4736: N-myc downstream regulated gene 1: A novel mediator of hypoxia-driven chemoresistance in glioblastoma. , 2012, , . | | 0 |
| 599 | Abstract 3797: Regulation and function of the mucin-like glycoprotein podoplanin in glioma.. , 2013, , . | | 0 |
| 600 | Abstract 3916: Differential roles of microglia and macrophages for glioma progression.. , 2013, , . | | 0 |
| 601 | Effect of Glioma N-Myc downstream regulated gene 1 (NDRG1) on the tumor microenvironment.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11587-11587. | 1.6 | 0 |
| 602 | Abstract 1803: Combining anti-Ang-2/VEGF-A therapy with radio- and chemotherapy in glioma. , 2017, , . | | 0 |
| 603 | Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12090-12090. | 1.6 | 0 |
| 604 | Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2076-TPS2076. | 1.6 | 0 |
| 605 | Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2013-2013. | 1.6 | 0 |
| 606 | Abstract 4238: DNA-methylation based epigenetic signatures predict and deconvolute somatic genomic alterations in gliomas. , 2019, , . | | 0 |
| 607 | Gliome des Erwachsenenalters. <i>Springer Reference Medizin</i> , 2021, , 1-12. | 0.0 | 0 |
| 608 | PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS. <i>Neuro-Oncology</i> , 2020, 22, iii429-iii430. | 1.2 | 0 |
| 609 | Neues zur Diagnostik und Therapie von Gliomen. <i>Neuroradiologie Scan</i> , 2020, 10, 199-214. | 0.0 | 0 |
| 610 | Diagnostic value of gadolinium contrast administration for spinal cord magnetic resonance imaging in multiple sclerosis patients and correlative markers of lesion enhancement. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110479. | 1.0 | 0 |
| 611 | PATH-23. OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE. <i>Neuro-Oncology</i> , 2021, 23, vi119-vi120. | 1.2 | 0 |
| 612 | PATH-27. MGMT PROMOTER STATUS IN IDH1/2 MUTANT ANAPLASTIC ASTROCYTOMA PATIENTS ASSESSED BY DNA METHYLATION PROFILING AND QMS-PCR: A REPORT FROM THE EORTC BRAIN TUMOR GROUP. <i>Neuro-Oncology</i> , 2021, 23, vi120-vi121. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 613 | IMMU-04. UNVEILING THE TUMOR-METABOLOME-IMMUNITY AXIS OF GLIOMA. Neuro-Oncology, 2021, 23, vi92-vi92. | 1.2 | 0 |
| 614 | TAMI-52. NEURONAL MECHANISMS OF BRAIN TUMOR INVASION. Neuro-Oncology, 2021, 23, vi209-vi209. | 1.2 | 0 |
| 615 | Response. Radiology, 2016, 279, 324-5. | 7.3 | 0 |